Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

J. Kelly, Ronan; A. Ajani, Jaffer; Kużdżał, Jarosław; Zander, Thomas; Van Cutsem, Eric; Piessen, Guillaume; Méndez, Guillermo; Feliciano, Josephine; Motoyama, Satoru; Lièvre, Astrid; E. Uronis, Hope; Elimova, Elena; Grootscholten, Cecile; Geboes, Karen; Zafar, Syed; Snow, Stephanie; H. Ko, Andrew; Feeney, Kynan; Schenker, Michael; Kocoń, Piotr; Zhang, Jenny; Zhu, Lili; Lei, Ming; Singh, Prianka; Kondo, Kaoru; M. Cleary, James; Moehler, Markus

doi:10.1056/nejmoa2032125

Public

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Published in New England Journal of Medicine • Mar 31, 2021

Authors:

Ronan J. Kelly

Jaffer A. Ajani

Jarosław Kużdżał

Abstract

BACKGROUND: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. METHODS: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled p...

Subject

Gastroesophageal Junction

Nivolumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!